INC Research LLC, a therapeutically focused global clinical research organization (CRO) with a Trusted Process® for delivering reliable results, today announced the appointment of Ian M. Braithwaite, PhD, as Executive Vice President and General Manager, General Medicine. Dr. Braithwaite brings extensive experience both in the CRO and biopharmaceutical industries to this key role providing global leadership for the Company’s General Medicine business unit, which specializes in conducting clinical trials in areas ranging from infectious disease, respiratory disease, women’s health, immunology and inflammation, gastrointestinal disease and ophthalmology. Dr. Braithwaite will be based out of INC’s Camberley, UK, office.
“We are excited to add an experienced leader like Dr. Braithwaite to our therapeutic leadership team,” says Jamie Macdonald, Chief Executive Officer. “Ian’s deep therapeutic experience both in the CRO and biopharmaceutical space provides a unique perspective on the efficient management of clinical development programs. As a CRO structured around a strong therapeutic focus, world-class leadership in our business units is critical to our success. The General Medicine business unit is our second-largest therapeutic group and a key piece our global infrastructure for serving customers worldwide in any therapeutic area. Ian is responsible for significantly growing our presence in this important fast-growing market segment.”
Dr. Braithwaite brings nearly 25 years of combined clinical development experience to leadership of this key unit with particular expertise in immuno-inflammatory diseases, including rheumatoid arthritis, lupus, transplantation, severe asthma and Crohn’s disease. He joins INC Research from PPD, where he served as Global Therapeutic Area Head, General Medicine. Dr. Braithwaite established and led the global General Medicine Therapeutic Area, aligning and integrating regional units into a worldwide organization. Under his leadership, this unit experienced significant growth in revenue and backlog, boosted staff utilization while reducing turnover and increased the number of proposals and new business wins in both traditional and new indications. Dr. Braithwaite previously served in other senior positions for PPD, including Executive Director and Therapeutic Head for Europe, Middle East and Africa, and Executive Director, Project Management Performance.
Prior to PPD, Dr. Braithwaite spent nearly a decade with AstraZeneca in senior clinical positions, most recently as Director, Clinical Development. He holds a doctorate in pharmacology from the University of Liverpool as well as a postgraduate diploma in clinical science from the Welsh School of Pharmacy at the University of Wales, Cardiff.
INC Research prides itself on its long-standing therapeutic heritage and extensive expertise in a broad range of areas, including Central Nervous System, Oncology, Cardiology, Endocrinology, Infectious Diseases, Immunology and Inflammation, Respiratory, Women’s Health, Gastroenterology, Dermatology and Ophthalmology. Therapeutic expertise is so important to the Company’s customers that the entire organization is structured around it. INC Research dedicates highly experienced business leaders, including Dr. Braithwaite, as therapeutic business unit heads to guide strategy and provide customers with the best possible foundation on which to build efficient, yet scientifically sound, clinical development programs.
Source: INC Research
Comments